Microbot Medical Inc. (NASDAQ:MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announces another step in its commitment to advance the commercialization processes of LIBERTY® with the signing of a manufacturing agreement with B.Y. Medimor Ltd.
The agreement governs the manufacturing of the Company’s LIBERTY® Robotic Surgical System, for its first in human clinical trial as well as for the initial LIBERTY systems that are expected to be marketed following the completion of regulatory requirements.
Medimor provides new product introduction (NPI) solutions and full turnkey manufacturing for medical devices as a one stop shop contract manufacturing service, including integration, parts cleaning, clean room assembly and testing.
“We continue our transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics,” commented Simon Sharon, Microbot’s CTO and General Manager. “We believe that the manufacturing agreement supports our efforts to deliver a state-of-the-art advanced robotic system and facilitates our next steps.”
